Latest news with #Bruton
Irish Independent
14-07-2025
- Business
- Irish Independent
Spanish firm sued for €7.4m over glazing in Exo Building
Bennett (Construction) Ltd, with a registered address in Mullingar, Co Westmeath, has brought proceedings against Spanish firm Tvitec System Glass SL and its Irish subsidiary sub contractor, Technical Envelope Facades (TEF) Ltd, formerly Tvitec System Ireland Ltd,, with a registered address in Mountainview Park, Tallaght, Dublin. It is claimed there was very bad leaking arising out of the works completed by TEF, and that the glazing supplied was defective. The workmanship of the installation of the glazing was of sub-standard quality, it is also alleged. The defendants deny the claims. An application was made by Thomas Hogan SC, for Bennett, to have the case admitted to the fast track Commercial Court. This was opposed by Michael Cush SC, for Tvitec, on grounds of delay in bringing the proceedings. Mr Justice Mark Sanfey refused to admit the case as he considered there had been culpable delay by Bennett in bringing the proceedings. It means the case will now be dealt with through the normal High Court list. In an affidavit Paul Bruton, managing director of Bennett, said his firm and TEF entered into an agreement in March 2018 for the supply and installation of glazing. TEF also entered into a collateral warranty with The Platform ICAV (formerly Davy Platform ICAV) which was the beneficiary of the project. The Spanish firm also executed a parent-company guarantee with The Platform whereby it guaranteed the obligations and liabilities of the Irish sub contractor, Mr Burton said. The benefit of the collateral warranty and guarantee was assigned to Bennett in August 2024. Mr Bruton said TEF began works in January 2018 and various issues arose, including cash-flow issues that TEF appeared to have on a regular basis, he said. In January 2022, following the Christmas break, TEF failed to return to site even though works were already significantly delayed, he claimed. A meeting between the parties followed and TEF advised that it had financial difficulties and that the works were not profitable. TEF said it would only return to site if a further €850,000 was paid. Bennett says it has paid €10.1m to TEF and another €625,000 "under duress" to get them back on site, Mr Bruton said. The company returned but failed to complete the works and once again left the site, he alleged. Under the terms of the collateral warranty, the dispute could be referred to a conciliator but TEF refused to nominate a conciliator and refused to accept one nominated by Bennett who, as a result, had to resign in December 2024. Bennett says it has embarked on extensive remedial works with different sub-contractors. Mr Bruton said the total sum being claimed against the defendants for the cost of remediating the works is €7.4m.
Dubai Eye
08-07-2025
- Health
- Dubai Eye
UAE first to approve oral therapy for rare autoimmune disorder
The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025
TAG 91.1
08-07-2025
- Health
- TAG 91.1
UAE first to approve oral therapy for rare autoimmune disorder
The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder. The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide. Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton's tyrosine kinase inhibitor to be approved for this condition. The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE's commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation. Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia #WamNews — WAM English (@WAMNEWS_ENG) July 8, 2025
Al Etihad
08-07-2025
- Business
- Al Etihad
Emirates Drug Establishment approves world's first oral therapy for immune thrombocytopenia
8 July 2025 14:37 ABU DHABI (WAM) The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatments in line with the highest international standards and by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.'Dr. Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications.'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.'She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
India.com
30-06-2025
- Lifestyle
- India.com
Sneaker Fever: Best Men's Casual Shoes You Can Grab on Flipkart
Planning an upgrade to your shoe game? Flipkart has you covered! With an enormous collection of cool, comfortable, and good-quality sneakers, you won't need to look anywhere else. You're heading to college, meeting friends, or need a relaxed day-to-day appearance. Flipkart offers the finest selection of sneakers from quality brands, featuring stylish designs that combine comfort with daily use. The shoes are perfect for both men who want great looks without compromising their comfort. Check out a few of the top ones available currently. 1. Bruton Premium Casual Sneakers for Men Image source- Order Now These are perfect Bruton sneakers that could be used in everyday life. They are a perfect match with jeans or joggers and shorts as well, due to their sleek and simple design. They are light, comfortable, and you just feel so good because they give a welcoming feeling to your outfit, a perfect way to wear them to college, a casual day, or even nights when you are hanging with your friends. Key Features: Refined lace-up closure Lightweight PU sole Stylish white finish Ventilated inner material Ideal for casual wear or college Not ideal for long outdoor walks on rough terrain. 2. U.S. Polo Assn. Planal 2.0 Sneakers for Men Image source- Order Now These U.S. Polo sneakers look sporty and fashionable as they were produced by a popular fashion house. They are convenient to wear every da,y and when coupled with jeans or trousers, they look very smart. It can be worn by men who need cool, branded shoes that blend with both casual and semi-formal clothes. Key Features: Durable canvas upper Brand tag detailing for genuineness Soft cushioned footbed Flexible outsole for ease Classic white and blue combination Canvas material gets dirty easily. 3. ASIAN Boston-01 Chunky Sneakers for Men Image source- Order Now These street fashion-forward, chunky sneakers are made for men. ASIAN makes these chunky sneakers thick-soled and stylish, adding height and comfort to your feet. From walking to dancing at the club, these sneakers make a fashion statement. Key Features: Chunky sole with fashionable design Soft memory foam cushioning Breathable mesh material Lightweight and supportive Stunning grip for outdoor wear Chunky fashion may not appeal to minimalist fashion lovers. 4. Killer Comfortable Outdoor Sneakers for Men Image source- Order Now Killer sneakers are a long-lasting comfort mix and an easy style. The design is clean, minimalistic, and it works very well as a day-to-day gadget or all-purpose outdoor tool. Key Features: Fashion faux leather upper Lace-up closure for a comfy, tailored fit All-day long wear comfort soles Slim and minimalist silhouette Long-wearing for day-in-day-out wear Not so breathable for those hot sunny days. Flipkart is the destination for sneaker enthusiasts! With a combination of budget-friendly, brand, and super-fancy choices, there's one for everyone. From minimalist designs to statement chunky designs, there is something for everyone. From Bruton's daily casual sneakers to ASIAN's streetwear chunky sneakers, and U.S. Polo's high-end brand to Killer's comfort that lasts, the shoes are designed to keep up with your style and pace. And there is online shopping, fast delivery, and genuine customer feedback on Flipkart to make your shopping tension-free and hassle-free. So go ahead. Treat your shoe closet now and walk tall. Disclaimer: At IDPL, we help you stay up-to-date with the latest trends and products. It should not be construed as an endorsement to buy. IDPL may make a very small commission from its sale if one chooses to buy the product from any of the links in this article.
